A targeting construct was designed to delete all exons of the locus and replace them with a neomycin resistance gene. The inactivation of the gene was confirmed by the defective response of mutant splenocytes compared with wild-type to treatment with anti-CD3 plus TSLP versus anti-CD3 alone. (J:108209)